Taurine treatment of dyskinesias: an attempt.
Taurine is a sulfonic amino acid with inhibitory effects in the central nervous system. The clinical effect of taurine on dyskinesias was tested in an open trial with 14 patients. Taurine (3 g/day) was given orally in divided doses. Six patients showed an initial improvement which, however, did not persist to the end of the 6-week treatment period. No side effects were observed. It seems unlikely that taurine administration will prove effective in the symptomatic treatment of dyskinesias.
Nyland
H
H
Department of Neurology, School of Medicine, University of Bergen, Norway.
Engelsen
B A
BA
Blom
H
H
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002114:Calcinosis / Q000188:drug therapy*; D002540:Cerebral Cortex / Q000187:drug effects*; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy*; D013654:Taurine / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*
D013654:Taurine